Maxim analyst Naz Rahman downgraded Galmed (GLMD) to Hold from Buy. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on GLMD: Galmed Pharmaceuticals Secures New Patent for NASH Therapy Galmed awarded extension of Aramchol patent protection to 2039 Biotech Alert: Searches spiking for these stocks today Disclaimer & DisclosureReport an Issue
